| Size | Price | |
|---|---|---|
| 5mg | ||
| Other Sizes |
| Targets |
This compound is a plasticizer that intercalates between polymer chains, reducing intermolecular forces and increasing flexibility; it has no defined biological receptor target.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
DOTP-d4 is not evaluated for biological activity; its unlabeled form, DOTP, is a high-molecular-weight plasticizer with low acute toxicity and is not estrogenic compared to phthalate alternatives. |
| ln Vivo |
In vivo activity is not applicable; DOTP-d4 is utilized solely as an analytical standard for quantification in biological and environmental samples.
|
| Enzyme Assay |
Binding assays are not relevant; the compound is analyzed by GC-MS or LC-MS/MS, where DOTP-d4 serves as an internal standard to correct for matrix effects and sample preparation losses in plasticizer residue analysis.
|
| Cell Assay |
Cell-based studies are not typical for plasticizer standards; if conducted, cells may be exposed to DOTP followed by extraction and quantification using DOTP-d4 as an internal standard in the analytical workflow.
|
| Animal Protocol |
Animal tissues (e.g., liver, adipose) collected from exposure studies are homogenized, extracted with organic solvents, and analyzed by LC-MS/MS using DOTP-d4 as an internal standard for accurate quantitation.
|
| ADME/Pharmacokinetics |
The unlabeled DOTP has low oral bioavailability, is rapidly metabolized to mono(2-ethylhexyl) terephthalate, and is excreted primarily in urine; the labeled analog has identical ADME properties.
|
| Toxicity/Toxicokinetics |
DOTP has low acute toxicity (LD50 >5,000 mg/kg in rats) and is not classified as a reproductive or developmental toxicant; the labeled analog is safe for analytical use under standard laboratory conditions.
|
| References |
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
|
| Additional Infomation |
This product is an analytical standard for research applications, not a therapeutic drug; it has no clinical trial status or regulatory approval as a pharmaceutical agent.
|
| Molecular Formula |
C24H34D4O4
|
|---|---|
| Molecular Weight |
394.58
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5343 mL | 12.6717 mL | 25.3434 mL | |
| 5 mM | 0.5069 mL | 2.5343 mL | 5.0687 mL | |
| 10 mM | 0.2534 mL | 1.2672 mL | 2.5343 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
